Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.52 |
| ▸ | HPGDS | O60760 | 3/20 | 0.51 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 4/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.41 |
| ▸ | MLNR | O43193 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072062 | 1.00 | USP30 (0.52) | USP30HPGDSDGAT2GPR119GABRA5 | |
| SCHEMBL2072065 | 1.00 | USP30 (0.52) | USP30HPGDSDGAT2GPR119GABRA5 | |
| SCHEMBL12776517 | 1.00 | USP30 (0.52) | USP30HPGDSDGAT2GPR119GABRA5 | |
| SCHEMBL12142190 | 0.90 | USP30 (0.52) | USP30HPGDSDGAT2GABRA5BACE1 | |
| SCHEMBL1365941 | 0.90 | USP30 (0.52) | USP30HPGDSDGAT2GABRA5BACE1 | |
| SCHEMBL1365943 | 0.90 | USP30 (0.52) | USP30HPGDSDGAT2GABRA5BACE1 | |
| SCHEMBL12776503 | 0.89 | HPGDS (0.59) | USP30HPGDSGPR119GABRA5WNT3A | |
| SCHEMBL12776688 | 0.88 | HPGDS (0.54) | USP30HPGDSGPR119GABRA5WNT3A | |
| SCHEMBL2070081 | 0.88 | HPGDS (0.54) | HPGDSWNT3AMLNR | |
| SCHEMBL12844647 | 0.88 | HPGDS (0.54) | HPGDSWNT3AMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2129660-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | Pfizer Products Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008075172-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | USP30 4416/4885HPGDS 984/4885DGAT2 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.